Prominent publications by Adeera Levin

KOL Index score: 17357

BACKGROUND: The effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on kidney failure, particularly the need for dialysis or transplantation or death due to kidney disease, is uncertain. Additionally, previous studies have been underpowered to robustly assess heterogeneity of effects on kidney outcomes by different levels of estimated glomerular filtration rate (eGFR) and albuminuria. We aimed to do a systematic review and meta-analysis to assess the effects of SGLT2 inhibitors ...

Also Ranks for: Sglt2 Inhibitors |  kidney failure |  type 2 |  systematic review metaanalysis |  egfr albuminuria
KOL Index score: 16802

BACKGROUND: Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium-glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes.

METHODS: In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, ...

Also Ranks for: Type 2 Diabetes |  renal outcomes |  hazard ratio |  canagliflozin lower risk |  endstage kidney disease
KOL Index score: 16361

BACKGROUND: Canagliflozin reduces the risk of kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, but effects on specific cardiovascular outcomes are uncertain, as are effects in people without previous cardiovascular disease (primary prevention).

METHODS: In CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation), 4401 participants with type 2 diabetes mellitus and chronic kidney disease were randomly ...

Also Ranks for: Chronic Kidney Disease |  type 2 |  renal outcomes |  kidney failure |  canagliflozin risk
KOL Index score: 16180

Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality in patients with end-stage renal disease (ESRD). Both in dialysis and in transplant patients, CVD remains the leading cause of death. There is accumulating evidence that the increase in CVD burden is present in patients prior to dialysis, due to both conventional risk factors as well as those specific to kidney disease. Of importance is that even in patients with mild kidney disease, the risk of ...

Also Ranks for: Patients Ckd |  cardiovascular disease |  chronic kidney |  ventricular hypertrophy lvh |  dialysis risk
KOL Index score: 15720

The incidence of cardiovascular disease (CVD) is very high in patients with chronic kidney (CKD) disease and in kidney transplant recipients. Indeed, available evidence for these patients suggests that the 10-year cumulative risk of coronary heart disease is at least 20%, or roughly equivalent to the risk seen in patients with previous CVD. Recently, the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (K/DOQI) published guidelines for the diagnosis and treatment ...

Also Ranks for: Kidney Transplant |  patients ckd |  managing dyslipidemias |  clinical practice guidelines |  treatment cvd
KOL Index score: 15549

BACKGROUND: Lowering LDL cholesterol with statin regimens reduces the risk of myocardial infarction, ischaemic stroke, and the need for coronary revascularisation in people without kidney disease, but its effects in people with moderate-to-severe kidney disease are uncertain. The SHARP trial aimed to assess the efficacy and safety of the combination of simvastatin plus ezetimibe in such patients.

METHODS: This randomised double-blind trial included 9270 patients with chronic kidney ...

Also Ranks for: Simvastatin Ezetimibe |  kidney disease |  renal protection |  myocardial infarction |  patients dialysis
KOL Index score: 15330

BACKGROUND: Canagliflozin reduced renal and cardiovascular events in people with type 2 diabetes in the CREDENCE trial. We assessed efficacy and safety of canagliflozin by initial estimated glomerular filtration rate (eGFR).

METHODS: CREDENCE randomly assigned 4401 participants with an eGFR of 30 to <90 ml/min per 1.73 m2 and substantial albuminuria to canagliflozin 100 mg or placebo. We used Cox proportional hazards regression to analyze effects on renal and cardiovascular efficacy and ...

Also Ranks for: Safety Outcomes |  173 egfr |  effects canagliflozin |  renal cardiovascular |  secondary analysis
KOL Index score: 14586

CONTEXT: Chronic kidney disease (CKD) is common. Kidney disease severity can be classified by estimated glomerular filtration rate (GFR) and albuminuria, but more accurate information regarding risk for progression to kidney failure is required for clinical decisions about testing, treatment, and referral.

OBJECTIVE: To develop and validate predictive models for progression of CKD.

DESIGN, SETTING, AND PARTICIPANTS: Development and validation of prediction models using demographic, ...

Also Ranks for: Kidney Failure |  predictive model |  progression ckd |  validation cohort |  estimated gfr
KOL Index score: 14581

The US Food and Drug Administration (FDA) and European Medicines Agency (EMA) are currently willing to consider a 30% to 40% glomerular filtration rate (GFR) decline as a surrogate end point for kidney failure for clinical trials of kidney disease progression under appropriate conditions. However, these end points may not be practical for early stages of kidney disease. In March 2018, the National Kidney Foundation sponsored a scientific workshop in collaboration with the FDA and EMA to ...

Also Ranks for: Scientific Workshop |  european medicines agency |  gfr albuminuria |  early stages |  drug administration
KOL Index score: 14121

The high prevalence of cardiovascular disease (CVD) in patients with kidney disease is well described. This Canadian, multicenter, observational cohort study reports the prevalence and risk factors of CVD associated with kidney disease, in a cohort of patients with established chronic kidney disease (CKD), who are followed-up by nephrologists. This analysis sought to answer 2 questions: (1) in patients with established CKD, are the prevalence and progression of CVD accounted for by ...

Also Ranks for: Kidney Disease |  cvd patients |  risk progression |  prevalence cardiovascular |  established ckd
KOL Index score: 13897

Chronic kidney disease (CKD) is a worldwide public health problem, with adverse outcomes of kidney failure, cardiovascular disease (CVD), and premature death. A simple definition and classification of kidney disease is necessary for international development and implementation of clinical practice guidelines. Kidney Disease: Improving Global Outcomes (KDIGO) conducted a survey and sponsored a controversies conference to (1) provide a clear understanding to both the nephrology and ...

Also Ranks for: Kidney Disease |  global outcomes |  position statement |  definition classification |  evidence base
KOL Index score: 13841

Left ventricular hypertrophy (LVH) is present in over 70% of patients commencing dialysis. It is an independent risk factor for cardiac death, which is the cause of death in approximately 45% of patients in dialysis. The prevalence of LVH in patients earlier in the course of renal insufficiency is unknown. As part of a prospective longitudinal study evaluating the progression of comorbid diseases in patients with progressive renal disease, we evaluated LVH. In 175 consecutive patients ...

Also Ranks for: Ventricular Hypertrophy |  lvh patients |  dialysis prevalence |  renal insufficiency |  systolic blood pressure
KOL Index score: 13472

BACKGROUND: The association between early changes in albuminuria and kidney and cardiovascular events is primarily based on trials of renin-angiotensin system blockade. It is unclear whether this association occurs with sodium-glucose cotransporter 2 inhibition.

METHODS: The Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial enrolled 4401 patients with type 2 diabetes and CKD (urinary albumin-creatinine ratio [UACR] >300 mg/g). ...

Also Ranks for: Credence Trial |  cardiovascular outcomes |  canagliflozin uacr |  heart failure |  hoc analysis

Key People For Kidney Disease

Top KOLs in the world
Andrew * *****
kidney disease serum creatinine glomerular filtration rate
Joseph ******
atherosclerosis risk kidney disease african americans
Tom * ******
kidney disease african americans blood pressure
John ****** *****
chronic kidney disease urinary incontinence interstitial cystitis
******** *******
global burden renal disease kidney transplantation
Adeera *****
kidney disease peritoneal dialysis british columbia

Adeera Levin:Expert Impact

Concepts for whichAdeera Levinhas direct influence:Kidney disease,  Chronic kidney disease,  Chronic kidney,  Kidney failure,  Peritoneal dialysis,  Acute kidney injury,  Kidney day,  Kidney diseases.

Adeera Levin:KOL impact

Concepts related to the work of other authors for whichfor which Adeera Levin has influence:Chronic kidney disease,  Acute kidney injury,  Renal function,  Heart failure,  Type 2 diabetes,  Patients ckd,  Cardiac surgery.



Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

University of British Columbia, Vancouver, British Columbia, Canada | Department of Medicine, University of British Columbia, Vancouver, Canada. | UBC Division of Nephrology, St Paul’s Hospital, Vancouver, BC, Canada | A Levin, Division of Nephrology